Skip to main content
Canna~Fangled Abstracts

The Effects of Chronic Marijuana Administration on 6-OHDA-Induced Learning & Memory Impairment and Hippocampal Dopamine and Cannabinoid Receptors Interaction in Male Rats

By March 9, 2023March 13th, 2023No Comments


doi: 10.1007/s11064-023-03899-8.

Online ahead of print.
Affiliations 

Abstract

There are general inhibitory effects of exo-cannabinoids on dopamine-mediated behaviors. Many studies suggested the interaction between cannabinoid receptors and dopamine receptors in the brain that affect cognition behaviors. In this paper, we investigate the effects of marijuana on 6-OHDA-induced cognitive impairments and the expression of dopamine and cannabinoid receptors in the hippocampus of male rats. 42 rats were divided into six groups. 6-hydroxy dopamine (6-OHDA) was administrated into the substantia nigra. Marijuana (60 mg/kg; i.p.) was administered 28 days, one week after the 6-OHDA injection. Morris water maze (MWM) and novel object recognition tests were performed. The hippocampal expression levels of cannabinoid receptors and D1 and D2 dopamine receptors evaluate by real-time PCR. The results showed marijuana improved the spatial learning and memory disorders caused by 6-OHDA in the MVM task and novel object recognition test. Additionally, the level of both D1 and D2 mRNA was decreased in 6-OHDA-treated animals and marijuana consumption only increased the hippocampal level of D1 mRNA. Moreover, the level of hippocampal CB1 mRNA in 6-OHDA- treated rats was higher than in control rats. However, the hippocampal level of CB2 mRNA was decreased in 6-OHDA- treated rats. Marijuana consumption caused a significant decrease in CB1 mRNA level and an increase in CB2 mRNA level in 6-OHDA + marijuana group. Therefore, marijuana may be helpful for learning & memory disorders, D1, and D2 dopamine receptors, and cannabinoid receptor alteration in patients with Parkinson’s disease.

Keywords: Cannabinoid receptors, Marijuana, Parkinson’s disease, cognitive impairments, dopamine D1 receptor, dopamine D2 receptor

Similar articles

References

    1. Galvan A, Wichmann T (2008) Pathophysiology of parkinsonism. Clin Neurophysiol 119:1459–1474 – DOI
    1. Esmaeili-Mahani S, Haghparast E, Nezhadi A, Abbasnejad M, Sheibani V (2021) Apelin-13 prevents hippocampal synaptic plasticity impairment in parkinsonism rats. J Chem Neuroanat 111:101884 – DOI
    1. Müller B, Assmus J, Herlofson K, Larsen JP, Tysnes O-B (2013) Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson’s disease. Parkinsonism Relat Disord 19:1027–1032 – DOI
    1. Latoo J, Mistry M, Dunne FJ (2013) Often overlooked neuropsychiatric syndromes in Parkinson’s disease,British Journal of Medical Practitioners,6
    1. Murray RM, Morrison PD, Henquet C (2007) Di Forti, Cannabis, the mind and society: the hash realities. Nat Rev Neurosci 8:885–895 – DOI

LinkOut – more resources



 

Leave a Reply